Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose IL-2 vs SBRT and High Dose IL-2 in Metastatic Renal Cancer
NCT02306954Phase 2Active, not recruiting
- Start
- Dec 2014
- Primary completion
- Sep 2020
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in renal cell carcinoma (RCC). Started Dec 2014; status: active, not recruiting.
02
Drugs
aldesleukin
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02306954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02306954.